The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone.Cette invention concerne une polythérapie à base d'un anticorps afucosylé anti-CD20 et de fludarabine et/ou mitoxantrone pour le traitement du cancer, et notamment, la polythérapie des cancers exprimant CD20 à base d'un anticorps afucosylé anti-B-Ly1 humanisé et de fludarabine et/ou mitoxantrone.
